News

This joint webinar will explore how Ukrainian clinicians and patient representatives can collaborate with European Reference Networks (ERNs) to strengthen rare disease care.

The European Society for Medical Oncology (ESMO) will host the ESMO Sarcoma and Rare Cancers Congress 2026 in Lugano, Switzerland, from 12–14 March 2026, bringing together leading clinicians, researchers and cancer experts from across Europe and beyond.

Season’s Greetings from EURACAN ✨ As the year comes to a close, we would like to thank all our members, partners, healthcare professionals, patient representatives, and collaborators for their engagement and commitment to improving care for patients with rare adult solid cancers across Europe.

The European Commission has published the first-ever Continuous Monitoring Report for the ERNs, confirming a 160% increase in new patients referred to ERN centres between 2018 and 2024.

We are proud to take part in this landmark gathering — the largest European initiative in healthcare — bringing together leading Comprehensive Cancer Centres (CCCs) across Europe with one shared mission: To build a strong and connected network of Comprehensive Cancer Centres across Europe by 2028.

The European Commission has opened a consultation on the draft Multiannual Financial Framework (MFF) — the EU’s long-term budget plan. In the current proposal, rare cancers and rare diseases are not explicitly mentioned, and the EU4Health programme no longer appears as a standalone initiative.

EURACAN held a high-level brainstorming session that brought together leading European experts to exchange ideas and define strategic directions for advancing care and research in rare cancers.

Join the Cancer Genomic Epidemiology course, 16–18 February 2026, for an immersive look at how genomics and epidemiology intersect to advance cancer research, clinical practice, and prevention.

EURACAN is proud to support SCAN 2025 – the Survey of Challenges in Access to Diagnostics, Treatments and Care for NET Patients, launched by our partner INCA (International Neuroendocrine Cancer Alliance).